Aelis Farma SA (69O.F)

12.90 -0.10 (-0.77%) At close: 08:22AM CEST

Aelis Farma SA

146 rue Lafaurie de Monbadon
Bordeaux 33 000
France
33 5 54 54 23 27
https://www.aelisfarma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 26

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Pier Vincenzo Piazza M.D., Ph.D.	CEO & Director	473.61k	N/A	1961
Ms. Marie Line Lefevre	Head of Finance	N/A	N/A	N/A
Stephanie Monlezun	Chief Operating Officer	N/A	N/A	N/A
Ms. Lea Floquet	Head of Legal	N/A	N/A	N/A
Mr. Arsene Guekam	Chief Corporate Development Officer	N/A	N/A	N/A
Ms. Sandy Fabre	Head of Discovery & IP Leader	N/A	N/A	N/A
Ms. Aurelie Boucard	Head of Preclinical Development	N/A	N/A	N/A
Ms. Helle Mengel	Head of Clinical Development	N/A	N/A	N/A
Ms. Corinne Chaimbault	Head of Pharmaceutical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.

Corporate Governance

Aelis Farma SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.